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ABSTRACT 
 
XINSHUO WANG: GSK-3 is Required for Axon Growth and Development 
(Under the direction of Dr. William Snider) 
 
Glycogen Synthase Kinase-3 (GSK-3) is a critical downstream regulator in 
multiple signaling pathways including neurotrophin/PI3K and Wnt/β-catenin pathways. 
GSK-3 signal has been strongly implicated in the regulation of neuronal polarity and 
axon growth in vitro. However, how GSK-3 is regulated and whether it is required for 
mammalian nervous system development is unknown. Here, I assessed the role of 
Par6 signaling in the regulation of GSK-3 activity and NGF-induced axon growth. My 
results show that Par6 is required for GSK-3 phosphorylation and inhibition. 
Elimination of Par6 inhibits NGF-induced axon growth. We have also generated 
nervous system specific GSK-3 knockout mice. By studying GSK-3 null cortical 
neurons, my results show that GSK-3 is required for axon growth in vivo and the 
deletion of GSK-3 mainly affects the microtubule dynamics which prevents the axon 
growth. We conclude that GSK-3 is a key regulator of axon growth and development 
both in vivo and in vitro. 
 iii
 
 
 
 
 
 
ACKNOWLEDGEMENT 
 
This study was performed from August 2005 to February 2009 in the 
Department of Cell and Molecular Physiology and Neuroscience Center in University 
of North Carolina at Chapel Hill, under the supervision of Dr. William Snider.  
Upon the accomplishment of my Master’s degree, I would first like to 
sincerely acknowledge my supervisor, Dr. William Snider, who has brought me to the 
most exciting research field and offered me a great project. I would also like to thank 
him for his patient supervision as well as extensive support both in this project and in 
daily life. During the time in his Lab, what I have learned from him is not only the 
knowledge of neuroscience, but also scientific skills to be a good scientist.  
I would like to express my gratitude to the following people for their support 
and assistance in my study: 
--- My committee members: Dr. Carol Otey, Dr. Suk-Won Jin, Dr. Mark Zylka 
and Dr. Mark Peifer. Thank you for being involved in my committee. 
--- Current and previous lab members: Dr. Woo-Yang Kim, Dr. Xiaoyan Li, Dr, 
Jason Newbern, Dr. Sarah Shoemaker, Dr. Jiang Zhou, Youjun Chen, Allison 
Overstreet, Levi Goins, Yaohong Wu, Dr. Fengquan Zhou, Dr. Mark Walzer and Dr. 
Jian Zhong. Thank you for your valuable help, discussions, suggestions and technical 
support.  
 iv
--- The members in Department: Dr. Ann Stuart and the fellow graduate 
students for helpful discussions in Presentation Class. Jan McCormick, Adriana 
Tavernise and Yvonne Cooper for their generous help. 
I sincerely say thanks to my husband for his persistent warm support. When I 
was almost exhausted by experiments, he gave me most of the consolations and 
motivation. Without his support, I would not have finished my degree successfully. 
Finally I am greatly indebted to my parent for their moral and intellectual supports and 
their encouragements. 
Thank you all! 
 v
 
 
 
 
 
 
 
TABLE OF CONTENTS 
LIST OF FIGURES ....................................................................................................vi 
LIST OF ABBREVIATIONS ...................................................................................... vii 
INTRODUCTION ....................................................................................................... 1 
Chapter 1 ................................................................................................................... 5 
INTRODUCTION ................................................................................................. 5 
RESULTS ............................................................................................................ 9 
DISCUSSION .................................................................................................... 17 
SUMMARY ........................................................................................................ 21 
Chapter 2 ................................................................................................................. 22 
INTRODUCTION ............................................................................................... 22 
RESULTS .......................................................................................................... 25 
DISCUSSION .................................................................................................... 32 
SUMMARY ........................................................................................................ 36 
MATERIALS AND METHODS .................................................................................. 37 
REFERENCES ........................................................................................................ 42 
 
 
 
 vi
LIST OF FIGURES 
Figure 1 Distribution of Par6 isoforms in various tissues. .................................... 9 
 
Figure 2 GSK-3β activity is regulated by Par6. .................................................. 11 
 
Figure 3 Par6α is required for efficient NGF-induced axon growth in E14 
DRG neurons. ............................................................................................. 12 
 
Figure 4: Introduction of Par6β to Par6α-decificent PC12 cells results in near 
normal amount of Par6 protein expression. ................................................ 12 
 
Figure 5: Par6 is required for neurite outgrowth in PC12 cells and CAD cells. .. 13 
 
Figure 6 Regulation of GSK-3β activity by Par6 signaling does not affect tau 
phosphorylation. ......................................................................................... 14 
 
Figure 7 Dishevelled-2 conditional knockout strategy. ....................................... 16 
 
Figure 8 Deletion of GSK-3 inhibits the cortical axon growth. ............................ 27 
 
Figure 9 GSK-3 null neurons have aberrant growth cone morphology. ............. 27 
 
Figure 10 Axon growth defects in GSK-3 null neurons can be rescued by 
re-expression of GSK-3. ............................................................................. 28 
 
Figure 11 Overexpression of Cre in vitro mimics axon growth defects in vivo. .. 29 
 
Figure 12 β-catenin overexpression in wild-type neurons does not mimic the 
axon growth defects in GSK-3 null neurons. ............................................... 30 
 
Figure 13 GSK-3 null neurons have excessively bundled microtubules in 
axons. ......................................................................................................... 32 
 
 
 
 vii 
LIST OF ABBREVIATIONS 
BAC: Bacterial artificial chromosome 
BSA: Bovine serum albumin 
CNS: Central nervous system 
CRIB: Cdc42/Rac-interactive binding 
CRMP2: Collapsin response mediator protein-2 
DIX: DIshevelled and AXin domain 
DMSO: Dimethyl sulfoxide 
EDTA: Ethylene-diamine-tetra-acetic acid 
EGFP: Enhanced green fluorescent protein 
FGF: Fibroblast growth factor 
GMP: Guanosine monophosphate 
GPCR: G-protein coupled receptor 
GTP: Guanosine-5’-triphosphate 
MDCK: Madin-Darby canine kidney cell line 
NFAT: Nuclear factor of activated T cells 
NGF: Nerve growth factor 
PB1: Phox and Bem1 domains 
PBS: Phosphate buffered saline 
PDZ: PSD95, Dlg, ZO-1 domains 
PI3K: Phosphatidylinositol 3-kinase 
PKC: Protein kinase C 
 viii
PNS: Periphery nervous system 
PVDF: Polyvinylidene fluoride 
RT-PCR: Reverse-transcript polymerase chain reaction 
RNA: Ribonucleic acid 
siRNA: small interfering RNA 
SEM: Standard error of the mean 
SDS-PAGE: Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 
 INTRODUCTION 
Glycogen synthase kinase-3 (GSK-3) is a widely expressed and highly 
conserved serine/threonine kinase. It was originally identified as key regulatory 
kinase that phosphorylates and inhibits glycogen synthase downstream of insulin 
signaling (Embi et al., 1980). However, it has since been shown to play far broader 
roles in many cellular processes (Cohen and Frame, 2001; Doble and Woodgett, 
2003). There are two mammalian GSK-3 isoforms encoded by distinct genes: 
GSK-3α and GSK-3β. The two proteins share 97% sequence similarity within their 
kinase catalytic domains, but differ significantly from one another outside this region 
(Woodgett, 1990). 
GSK-3 is unusual in that it is constitutively active in resting cells, and is 
primarily regulated through inhibition of its activity. GSK-3 phosphorylates a large 
number of substrates including cytoskeletal proteins, transcription factors, and 
metabolic regulators. It thus has prominent roles in the regulation of cellular 
morphology, gene expression, cell division, cell fate decisions, and apoptosis (Frame 
and Cohen, 2001; Jope and Johnson, 2004). Because of its importance, the activity 
of GSK-3 must be carefully regulated both temporally and spatially by mechanisms 
individually tailored for each substrate. The first chapter of my thesis describes a 
previously unknown regulatory mechanism of GSK-3 by the conserved 
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Par3/6-aPKCζ polarity complex in nervous system. 
In multicellular organisms, GSK-3 functions in several distinct signaling 
pathways (Doble and Woodgett, 2003; Woodgett, 2001). In response to growth 
factors such as FGF and NGF, phosphorylation of GSK-3 (serine-21 on GSK-3α and 
serine-9 on GSK-3β) by protein kinase B (PKB, aka Akt) causes GSK-3 inactivation. 
GSK-3 also plays a key inhibitory role in the canonical Wnt pathway. In unstimulated 
cells, GSK-3 phosphorylates β-catenin, thereby targeting it for ubiquitylation and 
proteasomal degradation. Exposure of cells to Wnts leads to inactivation of GSK-3 
through an as yet unclear mechanism involving the protein Dishevelled (Dvl). As a 
result, β-catenin is dephosphorylated and escapes the destruction machinery. 
Unphosphorylated β-catenin accumulates in the cytoplasm and translocates to the 
nucleus, where it becomes a transcriptional activator. The Hedgehog (Hh) pathway is 
somewhat similar to the Wnt pathway. In the absence of an Hh signal, GSK-3, 
together with other kinases, phosphorylates Cubitus interruptus (Ci) in flies or Gli in 
mammals to target it for proteolytic processing. The truncated Ci or Gli functions as a 
transcriptional repressor. Activation of Hh signaling results in translocation of 
unprocessed Ci or Gli to the nucleus where it activates Hh target genes. There are 
also studies showing that GSK-3 inhibition modulates signaling in Notch pathways in 
vitro (Espinosa et al., 2003; Foltz et al., 2002; Jin et al., 2008) and BMP pathways in 
Xenopus embryos (Fuentealba et al., 2007; Sapkota et al., 2007). More recently, the 
Akt/GSK-3 cascade has been found to be a new modality of G protein-coupled 
receptor (GPCR) signaling which provides a better biological understanding of 
psychiatric disorders (Beaulieu et al., 2007). All these pathways in which GSK-3 acts 
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as a key regulator, when dysregulated, have been implicated in the development of 
multiple human diseases. Given this association, GSK-3 has emerged as an 
attractive therapeutic target for the treatment of neurodegenerative diseases, 
non-insulin-dependent diabetes mellitus, inflammation and cancer (Cohen and 
Goedert, 2004; Meijer et al., 2004). 
Lithium was the first discovered GSK-3 inhibitor (Stambolic et al., 1996). 
Despite the fact that millimolar concentrations (20-30mM) of lithium are required to 
inhibit GSK-3 in cells, it has been broadly used to treat patients with mood disorders 
and in trials for treatment of Alzheimer’s disease and Amyotrophic Lateral Sclerosis 
(Fornai et al., 2008; Zarate et al., 2006; Zhong and Lee, 2007). Besides lithium, more 
than 50 inhibitors of GSK-3 have been identified and this list is growing (Ougolkov 
and Billadeau, 2008). GSK-3 inhibitors also have diverse effects on embryonic stem 
cells (ESCs). Sato et al. has shown that GSK-3 inhibition through 
6-bromoindirubin-3’-oxime (BIO) could maintain pluripotency of mouse and human 
ESCs (Sato et al., 2004). Further, Doble et al. reported enhanced retention of ESC 
markers in GSK3-α/β double knockout ESCs under differentiation conditions which 
further supports the idea (Doble et al., 2007). However, it is important to emphasize 
that the specificity of these compounds may not be restricted to GSK-3. For example, 
lithium has many other effects, including inhibiting adenylate cyclase and inositol 
monophosphatase (Quiroz et al., 2004; Williams et al., 2004). SB 216763, SB 415286 
and the Chiron inhibitors (Cline et al., 2002; Nikoulina et al., 2002) have been classed 
as more selective inhibitors of GSK-3. But this does not prove complete specificity 
(Martinez et al., 2002). A major difficulty in interpreting effects of GSK-3 inhibitors is 
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that there have been no genetic studies eliminating GSK-3 in the developing nervous 
system. Thus the effects of GSK-3 deficiency in the mammalian nervous system are 
not established. The second chapter of my thesis describes results of conditional 
mutagenesis experiments will address this issue.  
 
 
  
 
 
Chapter 1 
Regulation of GSK-3β activity and embryonic DRG axon growth by the 
Cdc42-Par3/6-aPKCζ polarity complex 
 
INTRODUCTION 
Recently, GSK-3β has emerged as a key regulator of axon morphogenesis 
downstream of many extracellular cues, such as neurotrophins, Wnts and 
Semaphorin 3A (Chadborn et al., 2006; Del Rio et al., 2004; Eickholt et al., 2002; Ito 
et al., 2006; Lucas et al., 1998; Zhou et al., 2004). Jiang et al. (Jiang et al., 2005) and 
Yoshimura et al. (Yoshimura et al., 2005) have shown that specification of rapidly 
elongating axonal processes versus more slowly growing dendritic processes in 
hippocampal neurons is regulated by GSK-3β activity. Spatially localized inactivation 
of GSK-3β by PI3K in a single immature neurite was necessary for future axon 
specification and maintenance, whereas global inactivation of GSK-3β led to the 
formation of multiple axons. We have also shown that in dorsal root ganglion (DRG) 
neurons, localized inactivation of GSK-3β at the growth cone is required for rapid 
axon elongation induced by NGF (Zhou et al., 2004) and complete inhibition of 
GSK-3 activity or loss of GSK-3 proteins prevent axon extension (Kim et al., 2006).  
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In spite of its importance, we still have a limited understanding of how 
regulation of GSK-3β activity occurs in neurons. Previous work in our lab has 
identified a pathway that links PI3K signaling to axonal microtubule assembly (Zhou 
et al., 2004). In this work, Zhou et al. showed that in an extending axon, PI3K is only 
activated at the distal tip and growth cone. The spatially localized PI3K signaling is 
then conveyed downstream through a similarly localized inactivation of GSK-3β. 
These two spatially coupled kinases control axon assembly by regulating a 
microtubule binding protein, adenomatous polyposis coli (APC). Although it is widely 
accepted that Akt is the key mediator of the serine-9 phosphorylation and inactivation 
of GSK-3β downstream of PI3K signaling (Cross et al., 1995), our unpublished data 
raise the possibility that alternative pathways may exist which also play important 
roles in regulation of GSK-3 function. For example, intergrin-linked kinase (ILK) has 
been shown to mediate NGF-induced axon growth and axon-dendrite polarity by 
leading to GSK-3β inactivation (Guo et al., 2007; Mills et al., 2003; Zhou et al., 2004). 
Cyclic GMP signaling can also regulate axon development through phosphorylation 
of GSK-3 (Zhao et al., 2009). 
Another way for PI3K to access GSK-3β may be through the conserved 
Par3/6-aPKCζ polarity complex. The partitioning-defective (Par) genes were initially 
identified in C. elegans for their roles in directing asymmetric cell division during early 
development (Cowan and Hyman, 2004; Kemphues et al., 1988). Par3, Par6 and 
atypical PKCζ form a large multiprotein complex which is activated by GTP bound 
Cdc42 (Henrique and Schweisguth, 2003; Joberty et al., 2000). Recent progress has 
been made in addressing the role of the polarity pathways in axon/dendrite 
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specification and spine morphogenesis where tight regulation of cytoskeleton 
dynamics is essential. In hippocampal neurons, the Par3/6-aPKCζ complex is 
recruited to the growth cone of one single neurite that will become future axon in a 
PI3K dependent manner (Shi et al., 2003). When overexpressed, Par3 and Par6 fail 
to localize correctly, leading to defects in polarization (Nishimura et al., 2004; 
Nishimura et al., 2005; Shi et al., 2003). Inhibition of aPKCζ activity prevents axon 
formation (Shi et al., 2003), whereas active (phosphorylated) aPKCζ can be seen at 
the tips of growing axons (Schwamborn and Puschel, 2004). Moreover, Par3 and 
Par6-aPKCζ have been shown to regulate dendritic spine morphogenesis in 
hippocampal neurons. Par3 is required for spine maturation (Zhang and Macara, 
2006) whereas Par6-aPKCζ is essential for spine biogenesis and maintenance 
(Zhang and Macara, 2008).  
Functionally, the Par3/6-aPKCζ complex is able to regulate astrocyte 
migration by controlling centrosome positioning (Etienne-Manneville and Hall, 2003a). 
Interestingly, GSK-3β has been placed downstream of the complex and the 
inactivation of GSK-3β is dependent on Cdc42 and aPKCζ activity. Phosphorylation 
of GSK-3β occurs specifically at the leading edge of migrating astrocytes and induces 
the interaction of APC with microtubules, which promotes cell polarization. These 
data begin to define a pathway for PI3K regulation of GSK-3β in astrocytes, however, 
no publications have addressed whether this pathway is also present in neurons.  
In the polarity complex, Par6 associates with aPKCζ through its N-terminal 
PB1 domain, with GTP-bound Cdc42 through a partial CRIB motif and with Par3 
through its PDZ domain. It is the critical adaptor which mediates the activation of the 
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whole polarity complex (Etienne-Manneville and Hall, 2003b; Henrique and 
Schweisguth, 2003). Solecki and colleagues initially addressed the role of Par6 in 
neurite outgrowth in cerebellar granular neurons using Par6 siRNA (Solecki et al., 
2004). They found disrupted axon extension in Par6-null neurons. Although this work 
suggested that blockade of axon growth in Par6 deficient neurons may be mediated 
by prevention of centrosome orientation, no downstream target of Par6 was studied. 
These data provide the initial basis for studying Par6 signaling in axon growth.  
The aim of this study was to assess the role of Par6 signaling in the 
regulation of GSK-3β activity and NGF-induced axon growth. This study used 
three systems: E14 DRG neurons plated on laminin in the presence of NGF, rat 
pheochromocytoma PC12 cells plated on poly-D-lysine (PDL) in the presence 
of NGF and mouse catacholaminergic CAD cells.  
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RESULTS 
Par6α is the only Par6 isoform that is expressed in DRG neurons, PC12 and 
CAD cells 
Four Par6 isoforms (α, β, δ and γ) have been identified in nonneuronal MDCK 
epithelial cells, but only α, β, γ have full length published mammalian sequences 
(Gao and Macara, 2004). Western blots have shown only a single band 
corresponding to Par6 in DRG neurons, PC12 cells and CAD cells. In order to 
determine which Par6 isoform(s) is/are present in the systems we were studying, we 
performed RT-PCR experiment. We designed isoform-specific primers to each of the 
three isoforms and ran RT-PCR on RNAs isolated from various tissues. Interestingly, 
we found only Par6α is expressed in DRG neurons, PC12 cells and CAD cells, 
whereas all three isoforms were expressed in varying degree in other tissues (Figure 
1). 
 
Figure 1 Distribution of Par6 isoforms in various tissues. Isoform-specific primers were used 
for RT-PCR on RNAs isolated from various tissues. Actin was used as a loading control. 
This result allowed us to design a Par6α specific siRNA to directly assess the 
effect of Par6 deficiency on GSK-3β activity and axon extension.  
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Par6α knockdown reduce NGF-induced GSK-3β inactivation 
Since Par6α is the only isoform expressed in DRG neurons, PC12 and CAD 
cells, we designed a Par6α specific siRNA construct to knockdown Par6α protein 
without affecting other Par6 isoforms. siRNA was introduced using the pSuper vector 
(Brummelkamp et al., 2002) which is engineered to harbor an EGFP expression 
cassette. Cells expressing this construct therefore expressed the EGFP reporter. The 
efficacy of the siRNAs was tested in PC12 and CAD cells. Par6 protein was 
dramatically reduced by four days post-transfection (Figure 2). Differentiated PC12 
cells were used in these experiments because we were unable to obtain high enough 
rate of transfection in DRG neurons to perform western blots.  
Upon NGF stimulation, GSK-3β is inactivated via phosphorylation on serine-9 
position. Re-addition of NGF to NGF-starved DRG or PC12 cultures induces dramatic 
upregulation of GSK-3β phosphorylation (Zhou et al., 2004). We used this model to 
test whether GSK-3β inactivation is mediated via Par6 signaling. PC12 cells were 
electroporated with Par6α siRNA and allowed to differentiate for 4 days in the 
presence of NGF. Differentiated Par6α-null PC12 cells were serum- and NGF-starved 
overnight and stimulated with NGF for a short period (15 minutes). Cell lysates were 
then collected and tested with western blots. In control cells, NGF stimulation induced 
huge elevated levels of GSK-3β serine-9 phosphorylation. However, Par6α deficient 
cells showed no significant changes on GSK-3β phosphorylation compared to 
baseline in response to NGF treatment (Figure 2).  
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Figure 2 GSK-3β activity is regulated by Par6. Top lane: Western blot of PC12 cells 
electroporated with control or Par6α siRNA and cultured for 4 days with NGF shown efficient 
knockdown of Par6α. Middle lane: Par6α knockdown significantly reduces NGF-induced 
phosphorylation of GSK-3β. Bottom lane: Total GSK-3β was used as a loading control.  
These data demonstrate that Par6 is required for NGF-induced serine-9 
phosphorylation of GSK-3β. 
 
Par6 is required for NGF-induced axon growth 
In order to address the effects of Par6 on axon growth in primary embryonic 
DRG neurons, E14 DRG neurons were electroporated with Par6α siRNA and 
cultured for 4 days in the presence of NGF. Neurons were then re-plated and cultured 
again with NGF. Par6α protein is strongly reduced over the 4 day period. Thus, 
re-plating allows the axon growth response to NGF in the setting of Par6α deficiency 
to be assessed. 24-hours following re-plating, the lengths of the longest axon were 
measured. We found that neurons deficient in Par6α grew axons only half as long as 
control transfected neurons (Figure 3, provided by Dr. Mark Walzer). Since the Par6β 
is resistant to the Par6α siRNA, we were able to co-transfect Par6α siRNA with 
full-length Par6β plasmid to rule out the off-target effects of the Par6α siRNA. As 
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shown in Figure 3, neurons expressing both Par6α siRNA and full length Par6β 
plasmid have a similar amount of axon growth. Furthermore, western blots done with 
PC12 cell lysates show the full recovery of Par6 protein expression after 
co-transfection of Par6β plasmid (Figure 4, provided by Dr. Mark Walzer). These 
results confirm that Par6α function is required for NGF-induced axon growth. 
 
Figure 3 Par6α is required for efficient NGF-induced axon growth in E14 DRG neurons. 
EGFP, Par6α siRNA-EFGP or Par6α siRNA-EGFP+Par6β-EGFP expressing DRG neurons 
were plated on PDL/laminin coated coverslips in the presence of NGF. Graphical 
quantification of the length of the longest axon (υm) 24h following re-plating shows significant 
reduction of axon growth after Par6α knockdown. Re-expression of Par6β into Par6α-null 
neurons rescues the axon growth. Data shown are means+SEMs. Figure is provided by Dr. 
Mark Walzer. 
 
 
Figure 4: Introduction of Par6β to Par6α-decificent PC12 cells results in near normal amount 
of Par6 protein expression as in control cells. Figure is provided by Dr. Mark Walzer. 
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Similar effects were also seen in Par6α deficient PC12 cells and CAD cells. 
PC12 cells respond to NGF by differentiation and elaboration of neurites (Greene and 
Tischler, 1976). Four days after transfection, control EGFP-expressing PC12 cells 
showed significant neurite growth while cells expressing the Par6α siRNA 
demonstrated little growth (Figure 5, top). CAD cells differentiate upon serum 
withdraw (Qi et al., 1997). Knocking down of Par6α in CAD cells causes significantly 
reduction in axon growth (Figure 5, bottom). 
 
Figure 5: Top: Par6 is required for neurite outgrowth in PC12 cells. Par6α siRNA-EGFP 
expressing PC12 cells do not elaborate neurites in response to NGF. Bottom: CAD cells 
differentiated by serum deprivation show reduction of neurite outgrowth compared with EGFP 
expressing cells. Quantification is not shown. 
These data suggest that Par6α is required for efficient elaboration of neurites 
by cell lines in response to differentiation-inducing treatments.  
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Par6 knockdown does not interfere with Tau phosphorylation. 
Tau is a major neuronal microtubule associated protein (MAP). One of its 
established functions is promotion of assembly and maintenance of microtubules 
structure (Drubin and Kirschner, 1986; Weingarten et al., 1975). The most important 
post-translational modification of tau is phosphorylation. The degree of 
phosphorylation regulates its microtubule-binding and tubulin-polymerizing activities 
(Lindwall and Cole, 1984). Hyperphosphorylated tau is unable to bind to microtubules 
thus leading to microtubule instability and altered axonal transport (Ballatore et al., 
2007). GSK-3 is a key kinase involved in tau phosphorylation. Hence we asked 
whether tau phosphorylation is affected by Par6α knockdown.  
GSK-3β phosphorylates tau at the serine 199/202 sites. The GSK-3 inhibitor 
6-bromoindirubin-3’-oxime (BIO) had a dose-dependent effect on tau phosphorylation 
at these sites (Figure 6, left panel). We expected to see hyperphosphorylated tau in 
Par6 null cells since GSK-3β activity is elevated in these cells. However, after Par6 
knockdown, no significant change of Tau phosphorylation on serine 199/202 sites 
was observed (Figure 6, right panel).  
 
Figure 6 Regulation of GSK-3β activity by Par6 signaling does not affect tau phosphorylation. 
Left panel shows that phosphorylation of Tau at serine 199/202 is regulated by GSK-3 activity. 
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Addition of GSK-3 inhibitor (BIO) shows dose-dependent inhibition on tau phosphorylation. 
Right panel shows that knocking down of Par6 does not impair Tau phosorylation at GSK-3 
sites. α-tubulin and β-actin was used as loading controls.  
These results mean that at this moment, we cannot tie Par6α regulation of 
GSK-3 activity to a specific cytoskeletal mechanism.  
 
Generation of a Dvl-2 conditional knockout mouse 
To explore other mechanisms that might be responsible for GSK-3 regulation 
in the setting of axon growth, we generated Dvl-2 floxed allele mice. Dishevelled (Dvl) 
proteins, of which three have been identified in humans and mice (Klingensmith et al., 
1996; Pizzuti et al., 1996; Semenov and Snyder, 1997; Sussman et al., 1994; Tsang 
et al., 1996) are highly conserved component of both the canonical Wnt and planar 
cell polarity (PCP) signaling cascades (Wallingford and Habas, 2005). In canonical 
Wnt pathways, dishevelled proteins function as essential scaffold proteins that 
transduce the signal activated by Wnt and inactivate GSK-3. Mouse knockouts for 
each of the Dvl genes have been generated. Distinct phenotypes of those mice 
reveal separate functions for each Dvl proteins. Dvl-1 knockout mice are viable and 
fertile, but display social interaction abnormalities and defects in sensorimotor gating 
(Lijam et al., 1997). By contrast, cardiac outflow tract abnormalities and rib/vertebral 
malformations are observed in Dvl-2 knockout mice (Hamblet et al., 2002). Dvl-3 
knockout mice also have cardiac outflow tract abnormalities and misorientated 
stereocilia in the organ of Corti as well (Etheridge et al., 2008). However, functional 
redundancy among Dvl genes is also suggested from their overlapping expression 
patterns and high degree of conservation. In support of this idea, Dvl double mutants 
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display phenotypes that were not observed and much more severer than the single 
Dvl knockouts, including a complete opening of the neural tube (Etheridge et al., 
2008; Wang et al., 2006).  
Functional redundancy among Dvl isoforms and early embryonic lethality in 
double knockout mice prompted us to generate a tissue specific Dvl double knockout 
mouse. Since Dvl-1 knockout mice are viable, fertile, and structurally normal; Dvl-2 
and Dvl-3 knockout mice have very similar phenotypes, we have decided to generate 
a Dvl-2 floxed allele line. With the help from the BAC engineering core facility in UNC 
neuroscience center, we have successfully generated the Dvl-2 conditional allele in 
which the region between exon 2 and exon13 on Dvl-2 gene has been floxed (Figure 
7). Deletion of those exons will result in a reading frame shift with no functional 
protein production. Currently, these mice are being bred to Dvl-1 null mice and 
different Cre lines to produce neuronal specific Dvl1/2 double knockout mice.  
 
Figure 7 Dishevelled-2 conditional knockout strategy. Diagrammatic representation of the 
construct used for generating a null allele (top), and the inactivated gene after homologous 
recombination (bottom).  
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DISCUSSION 
NGF-promoted axon growth requires Par6 signaling 
NGF has long been shown to be required for axon growth of DRG neurons 
both in vitro and in vivo (Tucker et al., 2001). It is well accepted that activation of 
specific transcription factors and the subsequent gene expression downstream of 
neurotrophin signaling pathways is necessary for efficient and sustained axon growth 
(Graef et al., 2003; Lonze et al., 2002). More recently, however, locally mediated 
transcription independent events have been identified which regulate axon growth at 
the level of cytoskeleton regulation.  
Growth cones at the tips of growing axons are the major sites where neurons 
receive and integrate extracellular signals to direct axonal cytoskeletal assembly 
(Baas and Luo, 2001). Axon elongation is initiated with growth cone advancement via 
actin polymerization at the leading edge. Subsequent microtubule polymerization and 
bundling are also the major events that mediate the formation of axons 
(Gordon-Weeks, 2004). For example, APC binds to the plus ends of microtubules 
and stabilize their growing ends (Zumbrunn et al., 2001). Zhou and colleagues found 
that NGF-induced axon growth requires phosphorylation of APC by GSK-3β, which 
abolished its stabilization properties (Zhou et al., 2004). Although the cytoskeletal 
mechanisms underlying axon growth and guidance have been extensively studied, 
how extracellular signals control the cytoskeletal dynamics, especially the 
microtubules remains a significant question. My work has characterized some of the 
upstream components that are required to regulate GSK-3β activity in the setting of 
NGF-induced axon growth.  
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Cdc42 is a member of the Rho GTPase subfamily and participates in many 
signaling pathways, but is particularly important in cytoskeletal remodeling 
(Etienne-Manneville and Hall, 2002). The Cdc42 interaction with a Par3/6-aPKCζ 
complex is conserved throughout animal evolution and is particularly required to 
specify and maintain the polarity of the nascent axon (Shi et al., 2003). Interestingly, 
Etienne-Manneville and Hall found that in migrating astrocytes, GSK-3β is present in 
a complex with Par6 and aPKCζ. Wounding results in a Cdc42-dependent inhibition 
of GSK-3β through phosphorylation on serine-9, which is in correlation with the 
dissociation of GSK-3β from Par6. APC also localizes to the leading edge in 
response to wounding, and this depends on activation of Cdc42 and aPKCζ or 
inactivation of GSK-3β (Etienne-Manneville and Hall, 2003a). This establishes a 
signaling pathway from Cdc42-Par6-aPKCζ-mediated inhibition of GSK-3β to the 
potential regulation of microtubule dynamics by APC. We found that similar signaling 
pathway exists in DRG neurons. Par6 likely plays the role of a scaffolding protein 
where upon activation via Cdc42, it allows for increased association of aPKCζ with 
GSK-3β in a multiprotein complex (our unpublished data). We also found Par6 is 
required for serine-9 phosphorylation of GSK-3β and NGF-induced axon growth. 
These data for the first time identify NGF as an extracellular signaling mediator that 
can access the polarity complex and show that the polarity complex is able to 
mediate microtubule dynamics through inactivation of GSK-3β. These are functions 
for the polarity complex that go beyond their established role in regulating the actin 
cytoskeleton.  
Our finding is in slight contrast to that of Solecki and colleagues who showed 
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that in Par6 deficient cerebellar granular neurons, axon extension was completely 
absent. They proposed that this was due to a lack of centrosome reoritation (Solecki 
et al., 2004). In our Par6 deficient DRG neurons, an axon still forms but axonal 
extension was significantly slowed. This discrepancy may be attributed to different 
neuron types with different signaling cascades responding to extracellular signals. In 
DRG neurons, NGF signaling is required for efficient axon extension whereas other 
extracellular signals may regulate initial elaboration of the axon in cerebellar neurons. 
In addition, Selocki et al. also showed that overexpression of Par6 disrupted axon 
extension in cerebellar neurons. This latter finding suggests that tight control of Par6 
levels in neurons is critical for axon growth.  
 
Regulation of GSK-3 phosphorylation and activity 
Zhou and colleagues’ work from our lab reported the GSK-3β-APC complex, 
normally considered a component of the Wnt pathway, can be accessed by 
neurotrophin signaling. This result is in conflict with the current view that GSK-3β in 
the Wnt complex appears to be insulated from signaling triggered by receptor 
tyrosine kinases (Cohen and Frame, 2001; Patel et al., 2004). Wnt treatment of 
HEK293 cells, which was effective in stabilizing β-catenin, caused a reduction in 
GSK-3β activity. However, this reduction in activity was not as a result of serine-9 
phosphorylation. Insulin treatment, although causing a reduction in GSK-3β activity 
and increasing serine-9 phosphorylation, did not affect β-catenin levels in the same 
cells (Ding et al., 2000). Experiments using Drosophila cells also came to the same 
conclusions (Matsubayashi et al., 2004; Papadopoulou et al., 2004). However, how 
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this compartmentalization is achieved and how broadly it applies is not clear. 
Although our results clearly shown that the cell polarity signaling complex could 
interact with the Wnt pathway and regulate GSK-3β activity via serine-9 
phosphorylation; this did not affect downstream Tau phosphorylation at serine 
199/202 which is GSK-3β site and does not require priming. This result indicates that 
Par6 regulation of GSK-3β might lead to some more different effects on microtubules, 
such as regulation of plus-end binding protein, APC. Another possibility is that GSK-3 
activity is also regulated by mechanisms other than serine-9/21 phosporylation. 
Recent mouse genetics show that when wild type GSK-3α and GSK-3β were 
replaced by mutants that cannot be phosphorylated at their N-terminus in vivo, the 
resulting mutant mice developed normally with no overt phenotype in the nervous 
system, although a defect in insulin signaling was present (McManus et al., 2005). 
There is also increasing evidence highlighting the distinct roles of GSK-3α in multiple 
aspects of cellular functions (Matsuda et al., 2008; Phiel et al., 2003), which indicates 
that phosphorylation of GSK-3α at the comparable serine-21 site may also play an 
important role in the regulation of GSK-3 functions. 
Besides the Cdc42-Par3/6-aPKCζ polarity signaling we have discussed 
above, dishevelled (Dvl) protein might also be an important regulator upstream of 
GSK-3 to study. Several lines of evidence make it promising. First, Dvl has multiple 
binding partners that are polarity proteins. One of them is the Lethal giant larvae (Lgl) 
protein which is required for the asymmetric targeting of cell fate determinants in 
neuronal precursors (Betschinger et al., 2003; Dollar et al., 2005; Klezovitch et al., 
2004). aPKCζ-dependent phosphorylation of Lgl has been shown to be essential for 
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Lgl function in cellular polarity (Hutterer et al., 2004; Plant et al., 2003). More recently, 
Dvl-1 was found to be colocalized with aPKCζ at the tips of hippocampal neurites and 
both of them are later enriched at the tip of the nascent axon. Dvl-1 association with 
aPKCζ increased its kinase activity in vitro (Zhang et al., 2007). MARK2/Par1 is 
known to regulate microtubule assembly in response to polarity cues and is one of 
the downstream mediators of aPKCζ to regulate neuronal polarity (Chen et al., 2006). 
Dvl-1 not only interacts with Par1 (Sun et al., 2001), but may inhibit MARK2 activity 
through aPKCζ activation as well (Zhang et al., 2007). This evidence suggests that 
Dvl might function in a large polarity complex. Second, Dvl also regulates GSK-3 
function via Axin, a negative regulator of the canonical Wnt pathway (Wallingford and 
Habas, 2005). Thus, Dvls may regulate axon growth via two mechanisms, an 
interaction with the polarity complex and via direct regulation of GSK-3 and its 
downstream target APC.  
 
SUMMARY 
The current work provides evidence for an important role of the 
Par3/6-aPKCζ polarity complex in regulating GSK-3β activity during NGF-induced 
axon growth in DRG neurons and PC12 cells. We found a significant reduction of 
NGF-induced axon extension coinciding with increased GSK-3β activity following 
knockdown of Par6. These results identified the Par3/6-aPKCζ polarity complex as a 
previously unrecognized mediator of NGF-induced axon growth potentially through 
acting as an upstream regulator of GSK-3. 
  
 
Chapter 2 
GSK-3 is a critical regulator of axon growth in vivo 
INTRODUCTION 
GSK-3 is a downstream convergent point for many axon growth regulatory 
pathways (Kim et al., 2006). Experimentally altering levels of GSK-3 activity has been 
shown to profoundly regulate neuronal morphology in vitro. Globally increasing 
GSK-3 activity dramatically reduces neurotrophin-induced DRG and hippocampal 
axon growth and interferes with hippocampal dendrite/axonal specification (Jiang et 
al., 2005; Yoshimura et al., 2005; Zhou et al., 2004). Globally inhibiting GSK-3 activity 
with pharmacological inhibitors also profoundly influences axonal and dendritic 
morphology of both PNS and CNS neurons. However, the studies with GSK-3 
inhibitors have inconsistent outcomes. Several studies have indicated that inhibition 
of GSK-3 activity by Wnts or lithium decreased axon elongation and induced axon 
branching in DRG and cerebellar neurons (Goold and Gordon-Weeks, 2005; Krylova 
et al., 2002; Lucas et al., 1998; Owen and Gordon-Weeks, 2003). Consistent with 
these results, Shi et al. (Shi et al., 2003) observed that global inhibition of GSK-3 
activity led to a defect in axon development in hippocampal neurons. However, Wnts 
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also reportedly stimulate the extension of postcrossing commissural axons 
(Lyuksyutova et al., 2003). Further, two recent studies showed that formation of 
multiple long axons was induced in hippocampal cultures in which GSK-3 activity was 
inhibited (Jiang et al., 2005; Yoshimura et al., 2005), consistent with the idea that 
global elimination of GSK-3 activity enhances axon growth. Thus, from the published 
work to date, it is not entirely clear whether global inhibition of GSK-3 enhances or 
inhibits axon growth. This confusion may arise from two aspects. Firstly, different 
pharmacological reagents used in these studies may have different efficacy to inhibit 
GSK-3 activity. Those differential effects may further affect GSK-3’s activity toward its 
substrates. This issue has been studied thoroughly and resolved by our lab (Kim et 
al., 2006). Secondly, we still do not quite understand what the mechanisms that 
regulate GSK-3 activity are and how they interact with each other.  
Despite many pharmacological studies showing important roles for GSK-3 
through development, GSK-3 single knock-out mice do not show very severe 
phenotypes. GSK-3α deficient mice are viable and only display enhanced glucose 
and insulin sensitivity accompanied by reduced fat mass (MacAulay et al., 2007). 
GSK-3β deficient mice did not exhibit an embryonic lethality until gestation; either via 
massive liver degeneration caused by an unexpected NF-κb-mediated hepatocyte 
apoptosis (Hoeflich et al., 2000) or via congenital heart defects caused by blunted 
cardiomyocyte differentiation (Kerkela et al., 2008). More importantly, dramatic 
defects in morphogenesis of nervous system and other organs have not been 
reported. Consistently, our lab has shown that the neurotrophin-induced axon growth, 
development of hippocampal neuronal polarity, and gross nervous system 
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development all occur surprisingly normally in GSK-3β null mice (Kim et al., 2006). 
The lack of effect of eliminating either isoform on morphological development has 
suggested the compensatory role from the other isoform.  
To further investigate the functions of GSK-3 on early brain development and 
axon growth in mammals, we generated GSK-3α null (MacAulay et al., 2007) and 
GSK-3β floxed allele mice (Patel et al., 2008) and crossed these with a Nestin-cre 
line (Tronche et al., 1999). The Nestin-cre line drives expression of Cre recombinase 
in CNS progenitor as early as E10 (Yokota et al., 2009). Neither GSK-3α-/- nor 
GSK-3βF/FNestin-cre mice exhibit major brain developmental malformations (our 
unpublished data). However, after crossing with the Nestin-cre line, conditional 
double null progeny die shortly after birth and have dramatic defects in brain 
development.  
The aim of this study is to understand how GSK-3 functions in vivo in 
the regulation of early brain development and axon growth  
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RESULTS 
GSK-3 deletion leads to massive hyperproliferation of neural progenitors 
Deletion of GSK-3α and GSK-3β in neural progenitors leads to massive 
hyperproliferation of neural progenitors. These results have been generated by Dr. 
Woo-Yang Kim and submitted for publication (Woo-Yang Kim, Xinshuo Wang, 
Yaohong Wu, Bradley Doble, Satish Patel, James Woodgett and William Snider. 
GSK-3 is a master regulator of neural progenitor homeostasis in mammals.). 
Although our intent was to study effects of GSK-3 deletion on axon growth in vivo, the 
massive disruption of brain development prompted me to take an in vitro approach for 
the initial studies.  
 
GSK-3 deletion leads to inhibition of axon formation 
In culture, cortical neuritogenesis follows a well defined set of stages (de 
Lima et al., 1997) similar to hippocampal neurons (Dotti et al., 1988). Stage 1 cortical 
neurons produce extensive lamellipodia and filopodia around their periphery. Stage 2 
neurons possess multiple neurites, but not an established axon. Stage 3 neurons 
extend a single axon from one of their multiple neurites.  
To explore a role for GSK-3 in neuritogenesis and/or axonogenesis, we 
cultured cortical progenitor cells from GSK-3 double mutant (GSK-3α-/- GSK-3βF/F 
Nestine-Cre) and control littermate (GSK-3α+/- GSK-3βF/W Nestine-Cre) brains at E14. 
Cells were grown on PDL/laminin coated coverslips in Neurobasal A media 
supplemented with B27 and glutamate for 5 days. Representative fields of cells fixed 
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on day 3 and day 5 are shown in Figure 8. Strikingly, after 48h in culture, the majority 
of cortical neurons (up to 90%) from double mutant brains remained in stage 1 or 2, 
with less than 10% reaching stage 3. However, those 10% neurons, which do 
proceed to stage 3, are positive for neuronal markers such as Tuj-1 and dendritic 
marker MAP2 (data not shown). This was in sharp contrast to cells from control 
brains, where less than 10% of neurons were in stage 2, and more than 90% 
developed to stage 3 (Figure 8). These effects were seen at every stage from E13 to 
E19. In addition, the growth cones of the longest processes were greatly enlarged in 
the double mutant neurons (Figure 9). The enlarged growth cones in the mutant 
neurons have clear filopodia protrusions, but are filled with long curved microtubules, 
whereas control growth cones were only partially penetrated by bundled microtubules 
(figure not shown). This is consistent with our previous pharmacology inhibitor results 
showing that when GSK-3 activity is completely eliminated by BIO at 100-300nM 
concentration, axon growth is inhibited and growth cones are greatly enlarged (Kim et 
al., 2006).  
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Figure 8 Deletion of GSK-3 inhibits the cortical axon growth. Cortical progenitors from GSK-3 
double mutant or control brain were dissociated and cultured on PDL/laminin coated 
coverslips for up to 5 days. Cells were fixed and stained with α-tubulin to visualize the 
morphology. Quantification of the length of the longest axon extended from each cell was 
shown on the right. Data shown are means+SEMs.  
 
Figure 9 GSK-3 null neurons have aberrant growth cone morphology. Growth cones from 
GSK-3 deficient cortical neurons were stained with α-tubulin (red in upper panel and green in 
lower panel) and F-actin (green in upper panel and red in lower panel).  
Similar axon growth and growth cone formation defects were also observed 
in DRG neurons taken from the double mutant embryos and cultured in vitro on 
PDL/laminin coated coverslips (figure not shown). These results suggest that GSK-3 
is required for axon growth and growth cone formation in cortical and DRG neurons. 
 
The defects in axon growth are cell autonomous 
To examine whether the observed axon growth defects were cell autonomous 
and specifically caused by GSK-3 ablation, we transfected wild-type GSK-3β plasmid 
into the GSK-3 null neurons by electroporation and cultured them for 4 days for 
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protein expression. As shown in Figure 10, mutant neurons transfected with GSK-3β 
were rescued in their ability to form axons while mutant neurons transfected with 
EGFP alone remain axonless.  
 
Figure 10 Axon growth defects in GSK-3 null neurons can be rescued by re-expression of 
GSK-3. Cortical progenitors taken from the double mutant brain were transfected with full 
length GSK-3β plasmid plus GFP or GFP alone as control. GSK-3β expression rescued the 
axon growth defects. Quantification of the length of the longest axon and numbers of axons 
from each GFP-positive cell was shown on the right. Data shown are means+SEMs. 
We also cultured cortical progenitor cells from GSK-3α-/- GSK-3βF/F and 
GSK-3α+/- GSK-3βF/W brains and overexpressed plasmid encoding the Cre 
recombinase to see whether Cre-mediated GSK-3 deletion in vitro had a similar effect 
on axon growth as seen in vivo. Results shown in Figure 10 confirmed the 
cell-autonomous effect of GSK-3 on axon growth. Only overexpression of Cre in 
GSK-3α-/- GSK-3βF/F cells, which removes all GSK-3 alleles, inhibited the axon 
growth. In control neurons, where GSK-3α and GSK-3β were still expressed, axons 
grow normally (Figure 11, provided by Dr. Woo-Yang Kim). 
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Figure 11 Overexpression of Cre in vitro mimics axon growth defects in vivo. Cortical 
progenitors taken from the GSK-3α+/- GSK-3βF/W or GSK-3α-/- GSK-3βF/F brains were 
transfected with Cre-EGFP plasmid or GFP as control. Cre overexpression in GSK-3α-/- 
GSK-3βF/F cells causes inhibition of axon growth as seen in vivo. Quantification of the length 
of the longest axon extended from each cell was shown on the right. Data shown are 
means+SEMs. Figure is provided by Dr. Woo-Yang Kim. 
These results suggest that GSK-3 functions cell autonomously, within cortical 
neurons, to mediate axon growth. 
 
Overexpression of β-catenin does not phenocopy the axon growth defects in 
GSK-3 null neurons 
GSK-3 is a key negative regulatory component in the canonical Wnt signaling 
pathway. In all cell types studied to date, GSK-3 acts to suppress cellular β-catenin 
levels by phosphorylating the protein and targeting it for proteosomal degradation. In 
GSK-3 double mutant brain, β-catenin is increased substantially (data not shown). To 
determine whether increased β-catenin levels in GSK-3 null neurons are responsible 
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for the axon growth defects, we overexpressed a stabilized β-catenin construct into 
wild-type neurons to mimic a GSK-3 null environment. This mutant form of β-catenin 
was made in such a way that it cannot be phosphorylated by GSK-3 thus it will not be 
degraded. Interestingly, we found overexpression of the stabilized β-catenin does not 
affect axon growth (Figure 12). Instead, it enhances the dendritic development (see 
arrows in Figure 12) with an increase in dendrite length and no change in dendrite 
numbers (Quantification not shown). This result is consistent with previous finding 
which identified β-catenin as a critical mediator of dendritic morphogenesis (Yu and 
Malenka, 2003).  
 
Figure 12 β-catenin overexpression in wild-type neurons does not mimic the axon growth 
defects in GSK-3 null neurons. Cortical progenitors taken from the wild type brain were 
transfected with stabilized β-catenin plus GFP or GFP alone as control and cultured for 4 
days. Cells were fixed and stained with α-tubulin or MAP2 in red.  
These results suggest that defects of axon growth in GSK-3 null neurons 
 31
were not due to increased cellular levels of β-catenin. 
 
GSK-3 null neurons have excessive bundled microtubule structures in axons 
Microtubules play an important role in axon specification. Axonal 
microtubules show increased stability and such stabilization probably allows 
microtubules to protrude with their dynamic ends more distally, thereby promoting 
axon formation (Witte et al., 2008). Many GSK-3 substrates are 
microtubule-associated proteins (MAPs) including APC, CRMP2, MAP1b, 
mictotubule-associated protein 2 (MAP2), tau, and neurofilament. GSK-3 
phosphorylation of those MAPs will modulate their affinities to microtubule, which 
further regulate microtubule growth and stability. To determine whether the axon 
growth defects were caused by altered microtubule dynamics, GSK-3 null neurons 
were stained with α-tubulin, one of the components of tubulin dimers. In control 
neurons, axonal microtubules have an intact structure. However, in mutant neurons, 
axons were filled with excessively bundled microtubules (Figure 13). Consistent with 
the hypothesis that GSK-3 deficiency leads to unstable microtubules, the level of 
acetylated tubulin (aged, stable form of tubulin) (Westermann and Weber, 2003), is 
also reduced in GSK-3 deficient neurons (data not shown).  
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Figure 13 GSK-3 null neurons have excessively bundled microtubules in axons. Cortical 
neurons taken from wild type and double mutant brain were cultured in vitro for 4 days and 
stained with α-tubule. Scale bars are shown.  
These results suggest that microtubule instability might be the major reason 
for axon growth inhibition in GSK-3 null neurons. 
 
DISCUSSION 
Loss of GSK-3 inhibits axon growth 
Although the role of GSK-3 in axon morphogenesis has been well established 
(Jiang et al., 2005; Yoshimura et al., 2005; Zhou et al., 2004), most of the supporting 
evidence comes from either treating cultured neurons with different pharmacological 
inhibitors or overexpressing various GSK-3 mutant constructs. There was no genetic 
evidence available in mammals until our group firstly characterizes the nervous 
system development in GSK-3β null mice (Kim et al., 2006). However, the brain, 
spinal cord, and DRGs of the null mice did not appear grossly different from the 
controls. The development of hippocampal neuron polarity was also normal.  
The potential compensation by GSK-3α is obvious since GSK-3α is 
abundantly expressed in the entire nervous system (Kim et al., 2006). We therefore 
used a conditional knockout strategy in a GSK-3α null background to target GSK-3β 
specifically in the developing nervous system by employing a mouse strain 
expression Cre recombinase under the control of the neural specifying elements of 
the Nestin promoter. The Nestin-cre transgene induces widespread recombination in 
the CNS neural progenitors from around embryonic day 10 (Yokota et al., 2009; 
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Zhong et al., 2007) and there is a complete depletion of GSK-3β in the nervous 
system in mice homozygous for a floxed GSK-3β allele (Dr. Woo-Yang Kim and Dr. 
William Snider, unpublished data).  
Severe failure of the brain development was found in the double mutant mice 
(Dr. Woo-Yang Kim and Dr. William Snider, unpublished data). Characterization of 
these double mutants reveals that the brain and spinal cord exhibit abnormalities in 
progenitor proliferation and axon growth and guidance (Dr. Woo-Yang Kim and Dr. 
William Snider, unpublished data). To further analyze how deletion of GSK-3 affects 
axon growth, we dissociated cortical progenitors from control and double mutant 
brain and cultured them in vitro on PDL/laminin coated coverslips. GSK-3 null 
neurons attached normally and the initial neurite sprouting within 24h was not 
significantly different from control neurons. After 24h, however, differences began to 
show. One of the neurites in control neurons extended much quickly than others and 
became an axon. In GSK-3 null neurons, none of the MAP2 positive neurites were 
able to extend further and form a Tau-1-positive axon.  
A possible reason for the lack of axon elaboration is loss of polarity cues. 
According to previous findings, localized inhibition of GSK-3 at one of the neurites is 
required for axon-dendrite specification. With no GSK-3 expression in these double 
mutant neurons, axon growth is strongly suppressed since no polarity cues were 
available. Re-expression of GSK-3β back into these double mutant neurons almost 
fully rescues the axon growth inhibition. Cre-mediated in vitro GSK-3 removal also 
faithfully mimiced the axon growth defects. These results present the first analysis of 
the physiological role of GSK-3 in the establishment of neuronal polarity and confirm 
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the critical requirement for GSK-3 in axon growth. These results also conform well 
with our previous studies of GSK-3 inhibitors and GSK-3 knockdown using siRNA in 
vitro (Kim et al., 2006).  
 
Beta-catenin or microtubule? 
β-catenin has dual functions in cells. It is an essential component of the 
canonical Wnt signaling system that controls decisive steps in development (Clevers, 
2006). Together with other members of the cadherin/catenin family, β-catenin also 
forms a major transmembrane signaling complex through which extracellular signals 
can influence the actin cytoskeleton (Gumbiner, 1996; Yap et al., 1997). In the 
nervous system, cadherin/catenin complex is present in neuronal processes during 
early development (Benson and Tanaka, 1998) and appears to play multiple roles 
during neural circuit formation and maturation (Abe et al., 2004; Togashi et al., 2002; 
Yu and Malenka, 2003).  
In the GSK-3 double mutant brain, β-catenin is increased substantially which 
is in consistent with the critical importance of GSK-3 in phosphorylating β-catenin in 
the destruction complex that mediates canonical Wnt signaling. It is thus reasonable 
to speculate that this aberrantly high level of β-catenin might be responsible for axon 
growth defects in GSK-3 null neurons. However, when a stabilized form of β-catenin 
is overexpressed in wild type neuron, the axon growth is largely unaffected (see 
Figure 12). There is only a moderate increase in dendritic length with no change in 
dendrite numbers. Yu et al. (Yu and Malenka, 2003) also shown that increasing the 
intracellular levels of β-catenin enhances dendritic arborization in rat hippocampal 
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neurons. They thought the effect was due to increased formation of the 
cadherin/catenin complex and likely tied to the effects on the actin cytoskeleton.  
GSK-3 also regulates microtubule growth and stability (Zhou and Snider, 
2005). It phosphorylates many microtubule associated proteins such as Tau, MAP1b, 
CRMP2 and APC. Mutations or the absence of these proteins modifies the axon 
growth and formation (Dawson et al., 2001; Gonzalez-Billault et al., 2001; Takei et al., 
1997; Takei et al., 2000; Teng et al., 2001; Yokota et al., 2009). GSK-3 
phosphorylation of microtubule associated protein such as MAP1b and tau appears 
to reduce their binding to microbutules, therefore maintaining a population of 
dynamically unstable microtubules (Trivedi et al., 2005). Thus, GSK-3 
phosphorylation can render the microtubules more dynamic, favoring axon growth. In 
turn, absence of GSK-3 stabilizes microtubules thus blocks the axon growth. This is 
exactly what we saw in the GSK-3 null neurons. Our result suggests that disruption of 
microtubule dynamics in the absence of GSK-3 might be the major cause of axon 
growth inhibition in GSK-3 null neurons.  
However, at this point, we still don’t know the exact mechanism for the lack of 
axon growth in GSK-3 null neurons. We favor dysregulation of the cytoskeletal 
dynamics but we don’t know the full differentiation status of the GSK-3 deficient 
neurons. There could be many other molecular abnormalities that contribute. 
Moreover, some of my unpublished results shown that PNS axon growth may bypass 
the requirement of GSK-3. Thus, the most important next step is to establish the 
relevance of these findings to axon growth in vivo. To that end, we have set up a 
number of crosses with different neuronal-specific Cre lines to assess axon growth 
 36
and targeting, such as sensory neuron specific Advillin-Cre (Hasegawa et al., 2007), 
pyramidal neuron specific Nex-Cre (Goebbels et al., 2006), retinal ganglion neuron 
specific Math5-Cre (Yang et al., 2003). 
 
SUMMARY 
This study examined the role of GSK-3 in neural development by conditional 
inactivation of GSK-3 in neural progenitor cells of the developing cortex. The current 
work provides strong evidence for the critical role of GSK-3 in neuronal axon growth 
and development. We found that deletion of GSK-3 inhibits axon growth in cortical 
and DRG neurons and the effect of GSK-3 is cell-autonomous. Loss of GSK-3 results 
in disrupted microtubule structure which might be the major reason for axon growth 
defects. These findings provide insights into the regulation of axon growth and the 
role of GSK-3 during nervous system development. 
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MATERIALS AND METHODS 
Antibodies 
The following primary antibodies were used: anti-pGSK-3β [Ser9] (Cell 
Signaling), anti-GSK-3β (BD Bioscience), anti-Par6 (N-18, Santa Cruz 
Biotechnology), anti-pTau [S199/202] (Invitrogen), anti-β-actin (Cell signaling), 
anti-α-tubulin (Sigma), anti-NF200 (Sigma) and anti-MAP2 (Millipore).  
The following secondary antibodies were used: HRP-conjugated donkey 
anti-mouse IgG (Dako), anti-rabbit IgG (Cell signaling) and bovine anti-goat IgG 
(Santa Cruz Biotechology). Alexa fluor-555 or Alexa fluor-488 conjugated phalloidin, 
anti-mouse and anti-rabbit antibodies (Molecular Probes). 
Plasmids 
Par6β wild-type plasmid is provided by Dr. Jeffrey Pessin (State University of 
NY at Stony Brook). Full length GSK-3β plasmid is provided by Xiao-Fan Wang (Duke 
University). Cre-EGFP plasmid is provided by Dr. Franck Polleux (UNC-Chapel Hill). 
Constitutively active β-catenin plasmids are generously provided by Dr. Bert 
Vogelstein (Johns Hopkins University) 
Animals 
Mice were cared for according to animal protocols approved by the University 
of North Carolina and University of Toronto. Nervous system-specific conditional 
GSK-3 double knockout mice (GSK-3α-/- GSK-3βF/F Nestin-Cre) were generated by 
mating GSK-3α null mice (McManus et al., 2005), floxed-GSK-3β mice (Patel et al., 
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2008), and Nestin-Cre mice (Tronche et al., 1999). Littermate GSK-3a+/- GSK-3bF/W 
Nestin-Cre mice served as controls. 
Inhibitors 
GSK3 inhibitor X (BIO), (2′Z, 3′E)-6-Bromoindirubin-3′-acetoxime was obtained 
from Calbiochem.  
Supplements 
Mouse NGF was obtained from Harlan Bioproducts. 
Oligos 
RT-PCR primer sequences are: Par6γ 5’ CTGCAGCGCTGTGGAAGTC, 
Par6γ 3’ TCTTCAAACTTCCCAGGCTTGT, Par6β 5’ 
GACAACTACCACAAGGCGGTTT, Par6β 3’ CCAAAGGCACTGTAGTCAGCTTCT, 
Par6α 5’ AAGAAAGGGCTCCTGCTACGA, Par6α 3’GACACCTGGCGGAAATCTTG 
The Par6α siRNA target sequence 
GCTGCTGGCGGTCAGTGATGAGATCCTTG, resides from 679-707bp downstream 
from the initiating methionine within the open reading frame of the mouse Par6α 
mRNA. The Par6 siRNA oligonucleotide sequence is as follows: 
GCUGCUGGCGGUCAGUGAUUU and was obtained from Dharmacon RNA 
Technologies.   
Total RNA isolation and RT-PCR 
Total RNA from cultured cells, embryonic DRG neurons or tissues was 
isolated using RNeasy Mini Kit (Qiagen) or Trizol (Invitrogen), as described by the 
manufacturer. Reverse-transcript PCR was performed by using Omnicript RT kit 
(Qiagen) and random primers (Invitrogen), as described by the manufacturer.  
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Cell Culture and Transfection 
Dissecting and culturing of mouse DRG neurons was performed as described 
previously (Markus et al., 2002). Briefly, pregnant CF-1 mice were euthanized and 
embryos removed at E13-14. DRGs were dissected and digested with collagenase 
(Roche) (1 mg/ml) for 15 min followed by trypsin-EDTA (0.25%) (Sigma) for 5 min at 
37°C. DRGs were then dissociated with a 1 ml pipette ti p in plating medium (MEM 
containing L-glutamine with 5% fetal bovine serum and 1X penicillin/streptomycin, 
Invitrogen) supplemented with antimitotics (20 mM 5-fluoro-2-deoxyuridine, 20 mM 
uridine, Sigma), electroporated with an Amaxa Nucleofector apparatus (Amaxa) then 
plated onto 24-well plastic culture dishes coated with poly-D-lysine (100 mg/ml) 
(Sigma) and laminin (10 mg/ml) (BD Bioscience) and cultured in the presence of NGF 
(50 ng/ml). DRGs were lysed with standard RIPA lysis buffer supplemented with 
protease and phosphatase inhibitors (Sigma) and stored at –80ºC for immunoblot 
analysis or fixed in 4% paraformaldehyde, coverslipped and analyzed for axon 
growth and morphology.   
For cortical neuron isolation, the two telencephalic hemispheres were 
isolated under sterile conditions in Ca2+/Mg2+-free PBS. Tissues were incubated for 
5min at 37°C in 0.25% Trypsin/EDTA (Sigma). The tissue  was then dissociated 
mechanically with 1ml Pasteur pipette, and plated in Neurobasal A medium 
supplemented with 1XB27, 2mM L-glutamate and 1X penicillin/streptomycin (all from 
Invitrogen). Cortical primary cells were then electroporated with an Amaxa 
Nucleofector apparatus (Amaxa). Electroporated cells were cultured on coverslips 
coated with poly-D-lysine/laminin same as for DRG neurons.  
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PC12 cells were maintained in DMEM/F12 (1:1) with 10% horse serum/5% 
fetal bovine serum on poly-D-lysine (100 mg/ml) coated culture dishes. For studies 
involving acute NGF treatment, cells were differentiated for 4 days in NGF (50ng/ml), 
serum and NGF starved overnight in DMEM/F12 (1:1) plus 0.3% BSA and acutely 
treated with NGF (50-100ng/ml). Cells were washed with PBS and lysed with 
standard RIPA lysis buffer supplemented with protease and phosphatase inhibitors 
(Sigma) and stored at –80ºC for immunoblot analysis. 
CAD cells were maintained in DMEM/F12 (1:1) with 8% fetal bovine serum on 
culture dishes. To induce differentiation, serum-containing medium was changed to 
serum-free medium and cells were further cultured for 3-4 days. 
Immunohistochemistry 
Following fixation in 4% paraformaldehyde for 15 min, embryonic DRG 
neurons or cortical neurons were blocked for 1 hour at room temperature and 
incubated in primary antibodies (see above) overnight at 4 degree. All antibodies 
were diluted in blocking buffer which is 1XPBS containing 2% BSA and 0.3% Triton 
X-100. The following day, neurons were washed in PBS, incubated in Alexa 
Fluor-conjugated secondary antibodies for 1 hr at room temperature, washed again 
with PBS and coverslipped with anti-fade mounting media for visualization. 
Image Capture and Axon Growth Analysis 
 Images were taken with a Zeiss LSM confocal microscope or a Nikon Eclipse 
epifluorescence microscope. For image analysis, Zeiss LSM 510 image browser and 
Metamorph software (Molecular Devices Corporation) were used. For axon length 
quantification, the longest axon from each transfected or control neuron was 
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measured by manually tracing with Metamorph software. At least 50 neurons with 
axons were selected in each experiment. All data are reported as mean+SEM 
followed by an unpaired Student's t test to determine the significance of the data 
between groups. 
Immunoblots 
Samples were separated on precast 4-12% SDS-PAGE gels (Invitrogen) and 
transferred to PVDF membranes (Amersham). The membranes were then blocked 
with 5% Blotting Grade Blocker Non-Fat Dry Milk (Bio-Rad) in PBS with 0.1% 
Tween-20 (Sigma), and incubated with primary antibody in blocking solution at 4°C 
overnight. The following day, membranes were wash with PBST and incubated with 
HRP-conjugated secondary antibody for 1 hour at room temperature in blocking 
solution and detected with ECL plus (Amersham) followed by exposure to Hyperfilm 
(Kodak).  
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